Bioxcel therapeutics announces update on nida-funded trial of bxcl501 (sublingual dexmedetomidine) for potential treatment of opioid use disorder (oud)

Columbia university-led trial expected to add fourth site to target completion of 4-arm, 160-patient trial in 2024 fentanyl adulterated or associated with xylazine (faax) designated an emerging threat by the white house office of national drug control policy 1 company to seek fda feedback on potential registrational paths new haven, conn., nov. 06, 2023 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced an update on the national institute on drug abuse (nida)-funded trial evaluating bxcl501 (sublingual dexmedetomidine) as a potential treatment for opioid use disorder (oud).
BTAI Ratings Summary
BTAI Quant Ranking